By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Korean molecular diagnostics firm Seegene today said it has raised $16.6 million in its initial public offering.

The company said it had sold 636,500 shares of its stock on the KOSDAQ (Korea Securities Dealers Automated Quotations) at KRW30,500 ($26.16) per share, and now has a market capitalization of $167 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.